This session reviews the physiologic, psychologic, and lifestyle factors that contribute to obesity as well as the health consequences of obesity with a focus on the kidney, such as focal segmental glomerulosclerosis and inability to qualify for transplant. Treatment options, including medications, and special considerations for the pediatric population are discussed.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 5/25/24.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):

Planning Committee Disclosures:
Christine Corbett, DNP, FNP-BC, CNN-NP, FNKF – Advisory Board Member for the National Kidney Foundation (NKF) and Speakers Bureau for GSK Anemia.

There are no other Planning Committee disclosures to declare.

Speaker Disclosures:
Talat Alp Ikizler, MD – Consultant for Fresenius Kabi and Nestle.

There are no other speaker disclosures to declare.

Commercial Support:
No commercial support declared.

Accreditation Statement:
The American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 17499.

ANNA urges participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
Upon completion of this activity, the learner will be able to discuss the implications and best practices related to pediatric obesity combined with kidney disease.